Khiron begins sales in Switzerland and expands its medical cannabis portfolio in Germany and the United Kingdom

Through its newly acquired EU-GMP distribution hub in Germany, Khiron expands its product portfolio and geographic reach within Europe to Germany, UK, and Switzerland.

• Switzerland: Khiron enters the Swiss medical cannabis market with the first sales of two of its new flower products, namely the KHIRON Gelato 19/1 and the first THC:CBD balanced flower product KHIRON Caramel 5/7
• UK: Marking the 1^st year anniversary of Zerenia™ Clinics UK, Khiron also initiated sales of three new exclusive products in the UK, consolidating a strong portfolio and improving selection for patients and prescribers
• Germany: After obtaining import approvals from German regulators, Khiron will start selling a total of seven medical cannabis SKU's in the upcoming weeks

TORONTO, Nov. 16, 2022 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), announces its market entry into Switzerland with initial sales of new products and increases its product offerings in Germany and UK.

In August 2022, Khiron completed the acquisition of its EU GMP-certified manufacturer and wholesaler, Pharmadrug GmbH in Germany. Since then, the Company has obtained import and export permits across Germany and the UK bringing to market its new product offerings, as well as looking for opportunities to expand its presence in other European markets.

The Alpine Republic of Switzerland has become the next market for Khiron, with Khiron's established reputation in Germany helping to pave the way. The start of the expansion is marked by the availability of the flower products KHIRON Gelato 19/1 and KHIRON Caramel 5/7, which are already very popular amongst patients and prescribers in our established markets.

Recently, a survey was conducted among all patients of Zerenia™ Clinics UK, with 100% of respondents stating that they are satisfied that their quality of life has improved since starting treatment. This service experience for patients is complemented by Khiron's steadily growing product portfolio, which has just recently been expanded with three additional exclusive varieties that will offer new treatment options for prescribers and patients.

Franziska Katterbach, President of Khiron Europe, comments: "Khiron continues its tradition of entering new markets early and furthering our goal of improving the lives of our patients in all our target markets. We are very excited to improve lives of patients in Switzerland as of now. I am equally pleased that our one-year anniversary of Zerenia™ Clinics UK is marked by the very good feedback from patients treated in our clinic. This reinforces our patient-first and quality first-approach which we will now bring to Switzerland as well."

Khiron is a leading global medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and focus on creating access to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Germany, the United Kingdom, Switzerland, Peru, and Brazil. The Company is led by its co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and board of directors.

Visit Khiron online at https://investors.khiron.ca.

LinkedIn: https://www.linkedin.com/company/khiron-life-sciences-corp/

This press release may contain "forward-looking information" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature constitutes forward-looking information. Forward-looking information contained in this news release may include statements pertaining to the expected synergies and benefits to the Company from the acquisition of the Target as well as statements as to business strategy. Forward-looking information and statements contained in this news release reflect management's current beliefs and is based on information currently available and on assumptions that management believes to be reasonable. These assumptions include, but are not limited to, the expected benefits to be realized by Khiron's business as a result of the acquisition of the Target, and assumptions regarding market opportunities in the jurisdictions in which the Company operates and where it seeks to operate.

Although management believes that its expectations and assumptions to be reasonable, forward-looking information is always subject to known and unknown risks, uncertainties and other factors, many of which are beyond the control of management, that may cause actual results to differ materially from those expressed or implied in such forward-looking information. Such risks and uncertainties include but are not limited to the following: general economic conditions, adverse conditions in capital markets, political uncertainties, counterparty risk, failing to obtain required regulatory requirements and approvals, failure to maintain required permits and licences, business integration risks, as well as those other risk factors discussed in Khiron's most recent annual information form which is available on Khiron's SEDAR profile at www.sedar.com.

As a result of the foregoing and other risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking information contained in this press release. Readers are further cautioned that the foregoing risks and uncertainties is not exhaustive, and there may be other risks and uncertainties, presently unknown to management of the Company, that may cause actual results to differ materially from those expressed or implied in forward-looking statements contained in this press release. The forward-looking information contained in this press release is expressly qualified by this cautionary statement. Khiron disclaims any intention to update or revise any forward-looking information disclosed herein, whether as a result of new information, future events or otherwise, except as required by law.

NEITHER THE TSX VENTURE EXCHANGE, NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VEMTIRE EXCHANGE), ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS PRESS RELEASE.

View original content to download multimedia:https://www.prnewswire.com/news-releases/khiron-begins-sales-in-switzerland-and-expands-its-medical-cannabis-portfolio-in-germany-and-the-united-kingdom-301680030.html

SOURCE Khiron Life Sciences Corp.